ADC Therapeutics to Hold Q1 2024 Financial Results and Pipeline Update Call on May 6, 2024

LAUSANNE, Switzerland, May 01, 2024 - ADC Therapeutics SA (NYSE: ADCT) is set to host a conference call and webcast on Monday, May 6, 2024, at 8:30 a.m. EDT to disclose its financial results for the first quarter of 2024. The event will also provide updates on key developments within its pipeline.

ADC Therapeutics, a frontrunner in the field of antibody drug conjugates (ADCs), is committed to revolutionizing treatment options for patients suffering from hematologic malignancies and solid tumors. The company's proprietary ADC technology has positioned it as a leader in the commercial-stage sector of this innovative field.

One of ADC Therapeutics' flagship products, ZYNLONTA (loncastuximab tesirine-lpyl), targets CD19 and has achieved accelerated approval from the FDA. Additionally, it has received conditional approval from the European Commission for patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. This drug is also being studied in combination therapies and for earlier lines of treatment, showcasing its potential versatility and efficacy.

Beyond ZYNLONTA, ADC Therapeutics has a robust portfolio of ADCs in various stages of clinical and preclinical development. This ongoing research underscores the company's dedication to expanding its therapeutic offerings and improving patient outcomes across a spectrum of cancers.

Headquartered in Lausanne, Switzerland, within the Biopôle life sciences campus, ADC Therapeutics also maintains operations in London and New Jersey. This strategic presence helps the company leverage global expertise and resources to bolster its research and development efforts.

ZYNLONTA® is a registered trademark of ADC Therapeutics SA, signifying its importance and proprietary status within the company's product lineup.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!